In the last trading session, 5.58 million Organon & Co (NYSE:OGN) shares changed hands as the company’s beta touched 0.71. With the company’s per share price at $13.16 changed hands at $0.44 or 3.46% during last session, the market valuation stood at $3.39B. OGN’s last price was a discount, traded about -75.53% off its 52-week high of $23.10. The share price had its 52-week low at $10.45, which suggests the last value was 20.59% up since then. When we look at Organon & Co’s average trading volume, we note the 10-day average is 4.25 million shares, with the 3-month average coming to 3.84 million.
Analysts gave the Organon & Co (OGN) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.75. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended OGN as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Organon & Co’s EPS for the current quarter is expected to be 0.89.
Organon & Co (NYSE:OGN) trade information
Instantly OGN was in green as seen at the end of in last trading. With action 17.08%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -11.80%, with the 5-day performance at 17.08% in the green. However, in the 30-day time frame, Organon & Co (NYSE:OGN) is -9.30% down. Looking at the short shares, we see there were 17.43 million shares sold at short interest cover period of 3.88 days.
The consensus price target for the stock as assigned by Wall Street analysts is 24, meaning bulls need an upside of 45.17% from its current market value. According to analyst projections, OGN’s forecast low is 24 with 24 as the target high. To hit the forecast high, the stock’s price needs a -82.37% plunge from its current level, while the stock would need to soar -82.37% for it to hit the projected low.
Organon & Co (OGN) estimates and forecasts
Year-over-year growth is forecast to reach -1.74% down from the last financial year.
Consensus estimates given by 4 financial analysts project the company’s revenue in the current quarter to hit an average of 1.51B. 4 analysts are of the opinion that Organon & Co’s revenue for the current quarter will be 1.54B. The company’s revenue for the corresponding quarters a year ago was 1.62B and 1.61B respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -7.02%. The estimates for the next quarter sales put growth at -3.98%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -23.49%. The 2025 estimates are for Organon & Co earnings to decrease by -5.92%, but the outlook for the next 5-year period is at 0.10% per year.
OGN Dividends
Organon & Co is expected to release its next quarterly earnings report on 2025-Feb-12. The 8.51% annual yield figure for the share gives it an annual dividend of 1.12. It is important to note, however, that the 8.51% dividend yield ratio should serve as a guide only, as you should also take into consideration many other aspects of a company’s operations and fundamentals before making any investment decision.
Organon & Co (NYSE:OGN)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.22% of Organon & Co shares while 82.27% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 82.45%. There are 82.27% institutions holding the Organon & Co stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 12.6625% of the shares, roughly 32.58 million OGN shares worth $674.39 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 11.7429% or 30.21 million shares worth $625.41 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were iShares Trust-iShares Core S&P Small-Cap ETF and Pacer Funds Trust-Pacer US Cash Cows 100 ETF . With 15.93 shares estimated at $209.58 million under it, the former controlled 6.17% of total outstanding shares. On the other hand, Pacer Funds Trust-Pacer US Cash Cows 100 ETF held about 4.31% of the shares, roughly 11.13 shares worth around $146.47 million.
